콘텐츠로 건너뛰기
Merck
  • CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.

CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.

NAR cancer (2021-01-02)
Junmei Cairns, Reynold C Ly, Nifang Niu, Krishna R Kalari, Erin E Carlson, Liewei Wang
초록

Cell division cycle 25 (CDC25) dual specificity phosphatases positively regulate the cell cycle by activating cyclin-dependent kinase/cyclin complexes. Here, we demonstrate that in addition to its role in cell cycle regulation, CDC25B functions as a regulator of protein phosphatase 2A (PP2A), a major cellular Ser/Thr phosphatase, through its direct interaction with PP2A catalytic subunit. Importantly, CDC25B alters the regulation of AMP-activated protein kinase signaling (AMPK) by PP2A, increasing AMPK activity by inhibiting PP2A to dephosphorylate AMPK. CDC25B depletion leads to metformin resistance by inhibiting metformin-induced AMPK activation. Furthermore, dual inhibition of CDC25B and PP2A further inhibits growth of 3D organoids isolated from patient derived xenograft model of breast cancer compared to CDC25B inhibition alone. Our study identifies CDC25B as a regulator of PP2A, and uncovers a mechanism of controlling the activity of a key energy metabolism marker, AMPK.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Anti-phospho-PP2A-α (pTyr307) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
ANTI-FLAG® M2 antibody, Mouse monoclonal, Clone M2, purified from hybridoma cell culture in bioreactor